Immunogenicity and immune tolerance coagulation Factors VIII and IX.
Some of the major issues related to the development and control of antibodies that occur during treatment of haemophilia with replacement factors (Factor VIII and Factor IX) are reviewed. Information on analytical issues, immunogenicity, and immune tolerance may be applicable to the study of other therapeutic proteins. Conversely, new information obtained from evaluation of other therapeutic protein products may address issues that remain unresolved for Factor VIII and FIX replacement therapy.
Rup
B
B
Bioanalytical Research & Development, Wyeth Research, Andover, MA 01810, USA. brup@genetics.com
D001323:Autoantibodies / Q000276:immunology; D005164:Factor IX / Q000276:immunology* / Q000627:therapeutic use; D005169:Factor VIII / Q000276:immunology* / Q000627:therapeutic use; D006467:Hemophilia A / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D007108:Immune Tolerance; D009500:Neutralization Tests; D012307:Risk Factors
D001323:Autoantibodies; D005169:Factor VIII; D005164:Factor IX